Epothilone B induces human ovarian cancer OV-90 cell apoptosis via external pathway

Environmental Toxicology and Pharmacology

Volumn 39, Issue 2, 2015, Pages 700-712

  Rogalska, Aneta ^a   Marczak, Agnieszka ^a  

^a UNIVERSITY OF LODZ   (Poland)

Author keywords

Apoptosis; Epothilone B; Paclitaxel; PARP; TRAIL; TUNEL

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; EPOTHILONE B; MULTIDRUG RESISTANCE PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; PHOSPHATIDYLSERINE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ABCB1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; CASPASE; EPOTHILONE DERIVATIVE; TNFSF10 PROTEIN, HUMAN;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; COLORIMETRY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOMETRY; DNA FRAGMENTATION; DNA REPAIR; DRUG POTENCY; ENZYME ACTIVATION; FEMALE; FLUOROMETRY; HUMAN; HUMAN CELL; IC50; IMMUNOBLOTTING; INTRACELLULAR SIGNALING; OV 90 CELL LINE; OVARIAN CANCER CELL LINE; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN CLEAVAGE; COMET ASSAY; DNA DAMAGE; DRUG EFFECTS; METABOLISM; OVARY TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASES; CELL LINE, TUMOR; COMET ASSAY; DNA DAMAGE; EPOTHILONES; FEMALE; HUMANS; OVARIAN NEOPLASMS; P-GLYCOPROTEINS; PACLITAXEL; POLY(ADP-RIBOSE) POLYMERASES; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84923253310     PISSN: 13826689     EISSN: 18727077     Source Type: Journal    
DOI: 10.1016/j.etap.2015.01.023     Document Type: Article

References (43)

1. Alberti C. Taxane- and epothilone-based chemotherapy: from molecule cargo cytoskeletal logistics to management of castration-resistant prostate carcinoma. Eur. Rev. Med. Pharmacol. Sci. 2013, 17:1658-1664.
2. Anselmo H.M., van den Berg J.H., Rietjens I.M., Murk A.J. Inhibition of cellular efflux pumps involved in multi xenobiotic resistance (MXR) in echinoid larvae as a possible mode of action for increased ecotoxicological risk of mixtures. Ecotoxicology 2012, 21:2276-2287.
3. Barbetti V., Tusa I., Cipolleschi M.G., Rovida E., Dello Sbarba P. AML1/ETO sensitizes via TRAIL acute myeloid leukemia cells to the pro-apoptotic effects of hypoxia. Cell Death Dis. 2013, 4:e536.
4. Baumgart T., Klautke G., Kriesen S., Kuznetsov S.A., Weiss D.G., Fietkau R., Hildebrandt G., Manda K. Radiosensitizing effect of epothilone B on human epithelial cancer cells. Strahlenther. Onkol. 2012, 188:177-184.
5. Bradley G., Naik M., Ling V. P-glycoprotein expression in multidrug-resistant human ovarian carcinoma cell lines. Cancer Res. 1989, 49:2790-2796.
6. Chaitanya G.V., Steven A.J., Babu P.P. PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration. Cell Commun. Signal 2010, 8:31.
7. Chaoui D., Faussat A.M., Majdak P., Tang R., Perrot J.Y., Pasco S., Klein C., Marie J.P., Legrand O. JC-1, a sensitive probe for a simultaneous detection of P-glycoprotein activity and apoptosis in leukemic cells. Cytometry B: Clin. Cytom. 2006, 70:189-196.
8. Chen J.G., Yang C.P., Cammer M., Horwitz S.B. Gene expression and mitotic exit induced by microtubule-stabilizing drugs. Cancer Res. 2003, 63:7891-7899.
9. Colombo N., Kutarska E., Dimopoulos M., Bae D.S., Rzepka-Gorska I., Bidzinski M., Scambia G., Engelholm S.A., Joly F., Weber D., El-Hashimy M., Li J., Souami F., Wing P., Engelholm S., Bamias A., Schwartz P. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer. J. Clin. Oncol. 2012, 30:3841-3847.
10. D'Amours D., Sallmann F.R., Dixit V.M., Poirier G.G. Gain-of-function of poly(ADP-ribose) polymerase-1 upon cleavage by apoptotic proteases: implications for apoptosis. J. Cell Sci. 2001, 114:3771-3778.
11. Dasari B., Jimmidi R., Arya P. Selected hybrid natural products as tubulin modulators. Eur. J. Med. Chem. 2014, 10.1016/j.ejmech.2014.10.062.
12. Forli S. Epothilones: from discovery to clinical trials. Curr. Top. Med. Chem. 2014, 14:2312-2321.
13. Gasiorowski K., Brokos B., Kulma A., Ogorzalek A., Skorkowska K. A comparison of the methods applied to detect apoptosis in genotoxically-damaged lymphocytes cultured in the presence of four antimutagens. Cell Mol. Biol. Lett. 2001, 6:141-159.
14. Griffin D., Wittmann S., Guo F., Nimmanapalli R., Bali P., Wang H.G., Bhalla K. Molecular determinants of epothilone B derivative (BMS 247550) and Apo-2L/TRAIL-induced apoptosis of human ovarian cancer cells. Gynecol. Oncol. 2003, 89:37-47.
15. Jimenez V.A., Alderete J.B., Navarrete K.R. Structural insight into epothilones antitumor activity based on the conformational preferences and tubulin binding modes of epothilones A and B obtained from molecular dynamics simulations. J. Biomol. Struct. Dynam. 2014, 1-15.
16. Kania K., Matlawska-Wasowska K., Osiecka R., Jozwiak Z. Analysis of aclarubicin-induced cell death in human fibroblasts. Cell Biol. Int. 2007, 31:1049-1056.
17. Kim E.H., Min H.Y., Chung H.J., Song J., Park H.J., Kim S., Lee S.K. Anti-proliferative activity and suppression of P-glycoprotein by (-)-antofine, a natural phenanthroindolizidine alkaloid, in paclitaxel-resistant human lung cancer cells. Food Chem. Toxicol. 2012, 50:1060-1065.
18. Kong Z., Raghavan P., Xie D., Boike T., Burma S., Chen D., Chakraborty A., Hsieh J.T., Saha D. Epothilone B confers radiation dose enhancement in DAB2IP gene knock-down radioresistant prostate cancer cells. Int. J. Radiat. Oncol. Biol. Phys. 2010, 78:1210-1218.
19. Larkin J.M., Kaye S.B. Potential clinical applications of epothilones: a review of phase II studies. Ann. Oncol. 2007, 18(Suppl. 5):v28L 34.
20. Le X.F., Mao W., He G., Claret F.X., Xia W., Ahmed A.A., Hung M.C., Siddik Z.H., Bast R.C. The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells. J. Natl. Cancer Inst. 2011, 103:1403-1422.
21. Lee J.J., Swain S.M. The epothilones: translating from the laboratory to the clinic. Clin. Cancer Res. 2008, 14:1618-1624.
22. Lee S.H., Son S.M., Son D.J., Kim S.M., Kim T.J., Song S., Moon D.C., Lee H.W., Ryu J.C., Yoon D.Y., Hong J.T. Epothilones induce human colon cancer SW620 cell apoptosis via the tubulin polymerization independent activation of the nuclear factor-kappaB/IkappaB kinase signal pathway. Mol Cancer Ther 2007, 6:2786-2797.
23. Lema M.J., Foley K.M., Hausheer F.H. Types and epidemiology of cancer-related neuropathic pain: the intersection of cancer pain and neuropathic pain. Oncologist 2010, 15(Suppl. 2):3-8.
24. McDaid H.M., Mani S., Shen H.J., Muggia F., Sonnichsen D., Horwitz S.B. Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study. Clin. Cancer Res. 2002, 8:2035-2043.
25. Paik D., Cocco E., Bellone S., Casagrande F., Bellone M., Siegel E.E., Richter C.E., Schwartz P.E., Rutherford T.J., Santin A.D. Higher sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with high versus low HER-2/neu expression in vitro. Gynecol. Oncol. 2010, 119:140-145.
26. Puiffe M.L., Le Page C., Filali-Mouhim A., Zietarska M., Ouellet V., Tonin P.N., Chevrette M., Provencher D.M., Mes-Masson A.M. Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer. Neoplasia 2007, 9:820-829.
27. Rogalska A., Gajek A., Marczak A. Analysis of epothilone B-induced cell death in normal ovarian cells. Cell Biol. Int. 2013, 37:1330-1339.
28. Rogalska A., Marczak A., Gajek A., Szwed M., Sliwinska A., Drzewoski J., Jozwiak Z. Induction of apoptosis in human ovarian cancer cells by new anticancer compounds, epothilone A and B. Toxicol. In Vitro 2013, 27:239-249.
29. Rogalska A., Szula E., Gajek A., Marczak A., Jozwiak Z. Activation of apoptotic pathway in normal, cancer ovarian cells by epothilone B. Environ. Toxicol. Pharmacol. 2013, 36:600-610.
30. Roque D.M., Bellone S., English D.P., Buza N., Cocco E., Gasparrini S., Bortolomai I., Ratner E., Silasi D.A., Azodi M., Rutherford T.J., Schwartz P.E., Santin A.D. Tubulin-beta-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones. Cancer 2013, 119:2582-2592.
31. Senovilla L., Vitale I., Martins I., Kepp O., Galluzzi L., Zitvogel L., Castedo M., Kroemer G. An anticancer therapy-elicited immunosurveillance system that eliminates tetraploid cells. Oncoimmunology 2013, 2:e22409.
32. Senovilla L., Vitale I., Martins I., Tailler M., Pailleret C., Michaud M., Galluzzi L., Adjemian S., Kepp O., Niso-Santano M., Shen S., Marino G., Criollo A., Boileve A., Job B., Ladoire S., Ghiringhelli F., Sistigu A., Yamazaki T., Rello-Varona S., Locher C., Poirier-Colame V., Talbot M., Valent A., Berardinelli F., Antoccia A., Ciccosanti F., Fimia G.M., Piacentini M., Fueyo A., Messina N.L., Li M., Chan C.J., Sigl V., Pourcher G., Ruckenstuhl C., Carmona-Gutierrez D., Lazar V., Penninger J.M., Madeo F., Lopez-Otin C., Smyth M.J., Zitvogel L., Castedo M., Kroemer G. An immunosurveillance mechanism controls cancer cell ploidy. Science 2012, 337:1678-1684.
33. Shiraki K., Yamanaka T., Inoue H., Kawakita T., Enokimura N., Okano H., Sugimoto K., Murata K., Nakano T. Expression of TNF-related apoptosis-inducing ligand in human hepatocellular carcinoma. Int. J. Oncol. 2005, 26:1273-1281.
34. Singh N.P., McCoy M.T., Tice R.R., Schneider E.L. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp. Cell Res. 1988, 175:184-191.
35. Suzuki-Karasaki M., Ochiai T., Suzuki-Karasaki Y. Crosstalk between mitochondrial ROS and depolarization in the potentiation of TRAIL-induced apoptosis in human tumor cells. Int. J. Oncol. 2014, 44:616-628.
36. Suzuki-Karasaki Y., Suzuki-Karasaki M., Uchida M., Ochiai T. Depolarization controls TRAIL-sensitization and tumor-selective killing of cancer cells: crosstalk with ROS. Front. Oncol. 2014, 4:128.
37. Vacchelli E., Aranda F., Eggermont A., Galon J., Sautes-Fridman C., Cremer I., Zitvogel L., Kroemer G., Galluzzi L. Trial watch: chemotherapy with immunogenic cell death inducers. Oncoimmunology 2014, 3:e27878.
38. Weigel T.L., Lotze M.T., Kim P.K., Amoscato A.A., Luketich J.D., Odoux C. Paclitaxel-induced apoptosis in non-small cell lung cancer cell lines is associated with increased caspase-3 activity. J. Thoracic Cardiovasc. Surg. 2000, 119:795-803.
39. Wennerberg E., Sarhan D., Carlsten M., Kaminskyy V.O., D'Arcy P., Zhivotovsky B., Childs R., Lundqvist A. Doxorubicin sensitizes human tumor cells to NK cell- and T-cell-mediated killing by augmented TRAIL receptor signaling. Int. J. Cancer 2013, 133:1643-1652.
40. Wolf B.B., Schuler M., Li W., Eggers-Sedlet B., Lee W., Tailor P., Fitzgerald P., Mills G.B., Green D.R. Defective cytochrome c-dependent caspase activation in ovarian cancer cell lines due to diminished or absent apoptotic protease activating factor-1 activity. J. Biol. Chem. 2001, 276:34244-34251.
41. Wu J., Guan M., Wong P.F., Yu H., Dong J., Xu J. Icariside II potentiates paclitaxel-induced apoptosis in human melanoma A375 cells by inhibiting TLR4 signaling pathway. Food Chem. Toxicol. 2012, 50:3019-3024.
42. Xu L., Hu X., Qu X., Hou K., Zheng H., Liu Y. Cetuximab enhances TRAIL-induced gastric cancer cell apoptosis by promoting DISC formation in lipid rafts. Biochem 2013, 438:285-290.
43. Ye L., He J., Hu Z., Dong Q., Wang H., Fu F., Tian J. Antitumor effect and toxicity of Lipusu in rat ovarian cancer xenografts. Food Chem. Toxicol. 2013, 52:200-206.